Core Viewpoint - Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of only 12-18 months post-diagnosis, and current treatments have limited efficacy in extending life expectancy [3] Group 1: Research Findings - A recent study published in Nature Cell Biology indicates that inhibiting lactate transport derived from tumor-associated macrophages (TAM) can restore cGAS-STING signaling and enhance antitumor immunity in glioblastoma [4] - The research team discovered that lactate is transported from TAM to glioblastoma stem cells (GSC) via MCT4-MCT1, promoting GSC proliferation and inducing lactylation modification of the non-homologous end joining protein KU70 at lysine 317 (K317), which inhibits cGAS-STING signaling and remodels the immunosuppressive tumor microenvironment [7] - Overall, the study reveals that lactate and lactylation modifications produced by TAM are key regulatory factors in maintaining the immunosuppressive tumor microenvironment in GSC, opening new avenues for combination therapies in glioblastoma [9]

Core Insights - Recent research indicates that autophagy is activated during exercise, mediating the health benefits associated with physical activity. However, the molecular mechanisms regulating skeletal muscle autophagy during exercise remain unclear [3][5]. Group 1: Research Findings - A study published in Cell Chemical Biology reveals that lactate produced during exercise enhances autophagy in skeletal muscle by lactylation of the mTOR protein [3][5]. - Lactate is identified as a positive regulator of autophagy in muscle cells, with levels rapidly increasing after a single exercise session [5]. - The study demonstrates that lactate promotes lactylation at the K921 site of the mTOR protein, inhibiting mTORC1 activity and enhancing autophagy [5][8]. Group 2: Implications - This research fundamentally redefines lactate, transforming it from a mere metabolic byproduct into a key signaling molecule that mediates exercise-induced skeletal muscle adaptation [7][8]. - The findings provide a conceptual framework for understanding how muscle metabolism translates into adaptive responses, opening new avenues for the treatment of muscle and metabolic diseases [8].

Core Insights - Lung cancer is a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases, and lung adenocarcinoma (LUAD) being the most common subtype. The five-year survival rate for lung adenocarcinoma patients is below 26% [2] - The study published in Cell Discovery reveals that ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing the degradation of ACSL4 in lung adenocarcinoma, identifying a key regulatory factor in the resistance to ferroptosis and proposing a new strategy for cancer treatment based on ferroptosis [3][8] Group 1: Ferroptosis and Cancer Treatment - Ferroptosis is a regulated form of cell death characterized by the accumulation of reactive oxygen species (ROS), lipid peroxides, and increased levels of divalent iron (Fe2+), showing significant effectiveness in overcoming resistance to traditional cancer therapies [5] - The study indicates that ferroptosis significantly increases lactate accumulation and subsequent protein lactylation, which contributes to the resistance of lung adenocarcinoma cells to ferroptosis [6] Group 2: Key Findings of the Research - SUMO2-K11 lactylation is identified as a critical factor determining the resistance to ferroptosis in lung adenocarcinoma, as it weakens the interaction between SUMO2 and ACSL4, promoting ACSL4 degradation and disrupting lipid metabolism [6][8] - AARS1 is recognized as the lactylation transferase for SUMO2-K11la, while HDAC1 acts as the de-lactylase. The research team developed a cell-penetrating peptide that specifically inhibits SUMO2-K11la, enhancing ferroptosis and increasing the sensitivity of lung adenocarcinoma to the chemotherapy drug cisplatin [6][8]